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ABSTRACT: Phenanthrenes have become the subject of intensive
research during the past decades because of their structural diversity
and wide range of pharmacological activities. Earlier studies
demonstrated that semisynthetic derivatization of these natural
compounds could result in more active agents, and oxidative
transformations are particularly promising in this regard. In our
work, a natural phenanthrene, juncuenin B, was transformed by
hypervalent iodine(III) reagents using a diversity-oriented approach.
Eleven racemic semisynthetic compounds were produced, the majority
containing an alkyl substituted p-quinol ring. Purification of the
compounds was carried out by chromatographic techniques, and their
structures were elucidated by 1D and 2D NMR spectroscopic
methods. Stereoisomers of the bioactive derivatives were separated
by chiral-phase HPLC and the absolute configurations of the active compounds, 2,6-dioxo-1,8a-dimethoxy-1,7-dimethyl-8-vinyl-
9,10-dihydrophenanthrenes (1a−d), and 8a-ethoxy-1,7-dimethyl-6-oxo-8-vinyl-9,10-dihydrophenanthrene-2-ols (7a,b) were
determined by ECD measurements and TDDFT-ECD calculations. The antiproliferative activities of the compounds were tested
on different (MCF-7, T47D, HeLa, SiHa, C33A, A2780) human gynecological cancer cell lines. Compounds 1a−d, 4a, 6a, and 7a
possessed higher activity than juncuenin B on several tumor cell lines. The structure−activity relationship studies suggested that the
p-quinol (2,5-cyclohexadien-4-hydroxy-1-one) moiety has a considerable effect on the antiproliferative properties, and substantial
differences could be identified in the activities of the stereoisomers.
Phenanthrenes are a rather uncommon class of aromaticsecondary metabolites and have a limited occurrence in
nature. They are presumably formed by oxidative coupling of
the aromatic rings of stilbene precursors.1 Hitherto, more than
460 phenanthrenes, among them mono-, di-, and triphenan-
threnes, were identified from different plant families, e.g.,
Orchidaceae, Juncaceae, Combretaceae, and Dioscoreaceae.2 A
large number of phenanthrenes with different substitution
patterns have been reported with various pharmacological
activities, such as antimicrobial, anti-inflammatory, cytotoxic,
antiproliferative, spasmolytic, antiallergic, and anxiolytic
effects.2,3 The most thoroughly investigated denbinobin, a
phenanthrenequinone, showed promising antiproliferative
activity.4−6 The mechanism of action of denbinobin involves
caspase-dependent and caspase-independent apoptosis of
colon cancer (COLO 205) cells.4 Moreover, by enhancing
the synthesis of reactive oxygen species (ROS), denbinobin
induces apoptosis in Jurkat leukemia and human lung
adenocarcinoma (A549) cells.5,7 A structure−activity relation-
ship study showed that the quinone substructure is required for
enhancement of mitogen-activated protein kinase (MAPK)-
independent ROS production activity.5 Another phenanthre-
nequinone, calanquinone A, differing from denbinobin by the
presence of an additional methoxy group, and synthetic
phenanthrenequinones also possessed cytotoxic activity on
different cell lines (HepG2, Hep3B, Ca9-22, A549, MCF-7,
MDA-MB-231, MRC-5). Structure−activity relationship stud-
ies showed that intramolecular hydrogen bonding between the
C-4 carbonyl and HO-5 in 3-methoxyphenanthrene-1,4-diones
may be necessary for the cytotoxicity.6
The phenanthrene dehydroeffusol showed activity against
two metastatic cancer cell lines, SGC-7901 (human gastric
carcinoma) and AGS (human caucasian gastric adenocarcino-
ma) in a dose-dependent manner (IC50 35.9 and 32.9 μM for
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SGC-7901 and AGS cells, respectively). Gastric cancer cell
mediated vasculogenic mimicry on SGC-7901 cells were also
inhibited by this compound using the tube formation assay.8
Dehydroeffusol effectively inhibited the gastric cancer cell
invasion and migration without exerting significant acute
toxicity.9 Juncusol was observed to be cytotoxic on HeLa cells;
treatment for 24 h increased the cell population in the G2/M
and sub-G1 phases.10 Juncuenin B possessed significant
antiproliferative activity against different human tumor cell
lines such as MDA-MB-231 (breast cancer), HeLa (cervical
cancer), and A2780 (ovarian cancer) with IC50 values 9.4, 2.9,
and 7.3 μM, respectively.10
The aim of this work was the semisynthetic modification of
juncuenin B (1,7-dimethyl-8-vinyl-9,10-dihydrophenanthrene-
2,6-diol) to prepare a variety of structurally related compounds
with higher antiproliferative activities. The experimental
approach was inspired by a 3-fold of reasons. First, the free
radical scavenging-related, oxidized metabolites of phenolic
compounds represent a chemical space particularly rich in
bioactive compounds.11 Second, we have recently demon-
strated that the hypervalent iodine(III) reagent [bis-
(trifluoroacetoxy)iodo]benzene (PIFA) may be efficiently
used to obtain product mixtures rich in such oxidized
scaffolds.12 Third, the p-quinol moiety, anticipated from a
PIFA-catalyzed oxidation of p-phenols, is the pharmacophore
of several potent inhibitors of ATR-dependent signaling,12,13 a
crucial mechanism of DNA damage response that is an
emerging antitumor target and a subject of many ongoing
clinical studies.14 Therefore, we followed a diversity-oriented
semisynthetic approach using two hypervalent iodine reagents,
PIFA, and (diacetoxyiodo)benzene (PIDA) to obtain oxidized
derivatives of juncuenin B. Furthermore, various alcohols
(MeOH, EtOH, and n-BuOH) were used as solvents to ensure
formation of a set of differently substituted derivatives. Eleven
chiral oxidation products (1−11), representing a wide
structural diversity, were obtained in this way as racemates
or stereoisomeric mixtures. Stereoisomers of the bioactive
derivatives were resolved by chiral-phase HPLC and absolute
configurations were assigned by ECD measurements and
TDDFT-ECD calculations. The antiproliferative activity of the
racemic compounds and separated optically active stereo-
isomers was investigated on MCF-7, T47D, HeLa, SiHa,
C33A, and A2780 cell lines, which enabled us to establish both
structure−activity and stereochemistry−activity relationships.
In order to gain insight into their tumor selectivity, the
compounds have also been tested on the NIH/3T3 cell line.
■ RESULTS AND DISCUSSION
Eleven racemic and enantiomerically pure chiral semisynthetic
derivatives (1−11) (Scheme 1 and Figure 1) have been
prepared from juncuenin B, a naturally occurring vinyl-
substituted achiral dihydrophenanthrene, in five transforma-
tions (I−V) by hypervalent iodine(III) reagents using a
diversity-oriented approach. PIFA and PIDA were used as
oxidants (PIFA in processes I−IV, PIDA in process V), under
different conditions, in MeCN−MeOH (process I), MeOH
(II), EtOH (III), n-BuOH (IV, V). PIFA and PIDA are well-
known reagents for the oxidation of phenols leading to the
formation of quinone-type products. This takes place through
an aryloxyiodonium(III) intermediate forming a phenoxenium
ion that undergoes a nucleophilic attack,15 but PIFA and PIDA
may also oxidize aromatic compounds via a single-electron
transfer mechanism.16 Following the oxidation, the mixture of
products were subjected to solid-phase extraction on silica to
remove the remaining oxidizing agent and the oxidation side-
products. The purification process was followed by MPLC and
HPLC.
During the reaction processes I−V, racemic mixtures of the
compounds were formed, all of them bearing p- or o-quinol
rings, substituted with methoxy-, ethoxy-, and n-butoxy groups
based on the solvent used. In the case of reaction IV, only
compound 10 could be isolated. It did not show structural
analogy with the aforementioned compounds; therefore, the
reaction was performed with PIDA under the same conditions
(process V). This reaction yielded 11, analogous to the
compounds derived from 4 and 7. As a result of chromato-
graphic purifications, compounds with one stereogenic center
were obtained as racemates (3, 4, 7−11), while compounds
with two stereogenic centers were isolated as diastereomeric
mixtures of two racemates (1a+1d, 1b+1c, 2a, 2b, 6a, 6b).
Separations of stereoisomers were performed using chiral-
phase HPLC when the mixtures of stereoisomers or the
racemates (1a−d, 4a,b, 7a,b) were found effective in the
antiproliferative assay. This was done in order to compare the
antiproliferative activity of the pure enantiomers and identify
not only 2D structure−activity but also stereochemistry−
activity relationships. The separation of the stereoisomers also
enabled the characterization and determination of the absolute
configurations of the bioactive derivatives by comparison of the
experimental and TDDFT-calculated ECD spectra.
The structure determination was carried out by extensive
spectroscopic analysis, using 1D and 2D NMR (1H−1H COSY,
HSQC, and HMBC) spectroscopy and ECD data analysis.
In the NMR spectra of 1a−1d, two sets of signals could be
identified that were attributed to two racemic diastereomers 1a
+1d and 1b+1c (ratio 1:1). The 1H NMR spectrum of the 1a−
1d mixture showed the presence of a pair of isomeric
compounds (1a+1d and 1b+1c) as some signals were
duplicated. Since these compounds are derived from juncuenin
B, similar signals were found in the 1H NMR spectrum: signals
of two o-coupled aromatic protons (δH 6.24, d and 7.23, d/
7.25, d), an aromatic proton singlet (δH 6.47/6.49), two
methyls (δH 1.46, s and 2.08, s), a vinylic system at δH 6.58, dd,
5.83, dd, and 5.69, dd (H-13, H2-14), and two methylene
groups (δH 2.63, m, 1.68, m/1.67, m and δH 2.83, m, 2.57, dd).
Two methoxy groups (δH 3.07, s and 2.92/2.93, s) were also
Scheme 1. Transformations of Juncuenin B under Different
Conditions
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detected in the 1H NMR spectrum (Table 1/1a+d and 1b+c).
The presence of two methylene signals (H2-9, H2-10)
indicated this isomeric pair to be 9,10-dihydrophenanthrene
derivatives. In the JMOD (J-modulated spin−echo experi-
ment) spectrum, 20 carbon signals were displayed (Table 2/1a
+d and 1b+c). In the 1H−1H COSY spectrum, correlations
were observed between δH 6.24, d and δH 7.23/7.25, d (H-3−
H-4), between δH 2.63, m, 1.68/1.67, m and δH 2.83, m, 2.57,
dd (H2-9−H2-10), and between δH 5.83, brd/5.69, dd and δH
6.58, dd (H-13−H2-14) (Figure 2). The location of the
methoxy groups was concluded from the HMBC spectra, as
proton signal at δH 3.07 (CH3O-1) showed correlations with
δC 83.8 (C-1), whereas the signal at δH 2.92/2.93 (CH3O-8a)
correlated with δC 73.2 (C-8a) (Figure 2). Thus, the C-2 and
C-6 hydroxy groups of juncuenin B were oxidized to carbonyl
groups (δC 202.6 and 185.9, respectively) and methoxy-
substituted dienone moieties were formed.
All of the above evidence confirmed the 2D structures of the
1a−1d isomers (Figure 2).
The NMR spectra of the mixture of 1b+1c were similar to
those of 1a+1d, only small differences were observed for the
CH3O-1, C-10, and C-11 resonances of 1a+1d and 1b+1c,
which suggested that these compounds are structurally related
to each other. Some 1H and 13C NMR signals were duplicated
in the spectra of 1b+1c, revealing the presence of a
diastereomeric pair as for 1a+1d.
After NMR studies the stereoisomers 1a−1d were separated
on a Lux amylose-1 chiral-phase column [tR = 13.6 min (1a),
17.4 min (1b), 21.6 min (1c), and 23.6 min (1d)].
Experimental ECD spectra indicated mirror-image relation-
ships between 1a/1d, and 1b/1c, respectively, verifying their
enantiomeric relationships (Figure 3).
In order to elucidate the absolute configurations of 1a−d,
the solution TDDFT-ECD method was applied to (1R,8aR)-1
and (1R,8aS)-1.17 The initial Merck Molecular Force Field
(MMFF) conformational search resulted in nine conformers
for each in a 21 kJ/mol energy window, respectively. These
geometries were reoptimized at the ωB97X/TZVP PCM/
MeCN level18 resulting in three conformers for both
stereoisomers (Figures S8 and S9, Supporting Information).
ECD spectra were computed at various levels and compared to
the experimental spectra of 1a−1d. There were only minor
differences in the experimental ECD spectra of 1a versus 1b
and 1c versus 1d, and the computed ECDs are mainly
influenced by one of the two chirality centers. Boltzmann-
averaged ECD data of both (1R,8aR)-1 and (1R,8aS)-1 gave
acceptable to good agreement with the experimental data of 1a
and 1b with the C-1 stereogenic center definitively influencing
the ECD profile (Figure 4). Thus, the absolute configuration of
this stereocenter could be determined as (1R) for the first- and
second-eluted stereoisomers 1a and 1b and (1S) for the third-
and fourth-eluting 1c and 1d. The shape of the B3LYP/TZVP
PCM/MeCN and PBE0/TZVP PCM/MeCN ECD spectra of
(1R,8aR)-1 reproduced the experimental ECD curve of 1a
better, while those of (1R,8aS)-1 were similar to the
experimental spectrum of 1b (Figure 5). The better agree-
ments allowed tentative assignment (8aR) for 1a and (8aS) for
1b. DFT-NMR calculations of the B3LYP/6-31+G(d,p)
conformers of (1R ,8aR)-1 and (1R ,8aS)-1 at the
mPW1PW91/6-311+G(2d,p) level19 could not differentiate
Figure 1. Structures of the prepared compounds 1−11.
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the epimers due to the small chemical shift differences of the
experimental values.20
The 1H NMR spectrum of compound 2a showed signals
characteristic of juncuenin B analogues: signals of two o-
coupled aromatic protons (δH 6.45, d and 6.61, d), one
aromatic proton singlet (δH 6.84), two methyl singlets (δH 1.97
and 2.02), a vinyl group at δH 6.50, dd, 5.78, dd and 5.63, dd,
two methylene groups (δH 1.92, m, 2.45, m, and δH 2.35, m,
2.83, m), and two methoxy singlets (δH 2.72 and 3.04),
respectively (Table 1). In the JMOD spectrum, signals of 20
carbon atoms were detected (Table 2). In the 1H−1H COSY
spectrum, correlations between δH 6.45, d and 6.61, d (H-3−
H-4), between δH 2.35, m, 2.83, m, and δH 1.92, m, 2.45, m
(H-9−H-10), and between δH 6.50, dd, and 5.78, dd, 5.63, dd
(H-13−H2-14) were observed. The position of the methyl
groups were determined based on the HMBC correlations of
the methyl protons at δH 1.97 and 2.02 with C-1 (δC 133.0)
and C-7 (δC 134.1), respectively. Methoxy groups attached at
C-4a and C-8a were positioned by means of the HMBC
interactions between δH 3.04 (CH3O-4a) and δC 73.1 (C-4a),
and between δH 2.72 (CH3O-8a) and δC 75.1 (C-8a). The
vinylic system was connected to C-8 via cross peaks between
δH 5.63, dd, 5.78, dd and δC 150.2.
All NMR characteristics of compound 2b were similar to
compound 2a, indicating that they are diastereomers. The
main differences between 2b and 2a were found between the
13C NMR chemical shifts of C-4a and 8a and adjacent carbons,
suggesting that 2b and 2a differ in the configurations of C-4a
and 8a.
In the case of racemic compound 3, the signals of four o-
coupled aromatic protons [(δH 6.30, d and 9.06, d (H-3−H-4),
δH 8.19, d and 7.60, d (H-9−H-10)], two methyls (δH 1.58, s
and 2.42, s), a vinyl group (δH 6.98, dd, 5.82, dd and 5.38, dd,
H-13 and H2-14), and two methoxy groups (δH 3.08, s, and
3.79, s) were detected in the 1H NMR data (Table 1). The
differences between juncuenin B and compound 3 involved the
Figure 2. Diagnostic COSY (−) and HMBC (H→ C) correlations of
compounds 1a−d.
Figure 3. (a) Experimental ECD spectra of 1a−1d in MeCN and (b)
experimental UV spectra of 1a/1d and 1b/1c in MeCN.
Figure 4. Experimental ECD spectrum of 1a in MeCN (black line)
compared with the calculated PBE0/TZVP PCM/MeCN spectrum of
(1R,8aR)-1 (purple line). Level of DFT optimization: ωB97X/TZVP
PCM/MeCN. Bars represent the rotational strengths of conformer A.
Figure 5. Experimental ECD spectrum of 1b in MeCN (black line)
compared with the calculated B3LYP/TZVP PCM/MeCN spectrum
of (1R,8aS)-1 (red line). Level of DFT optimization: ωB97X/TZVP
PCM/MeCN. Bars represent the rotational strengths of conformer A.
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presence of an aromatic ring B, the oxidation of the phenolic
group at C-2 to a carbonyl moiety (δC 202.4), and the addition
of methoxy groups at C-1 and C-5.
The 1H NMR spectrum of the racemic mixture of 4a and 4b
differ from juncuenin B in the presence of a methoxy group
(δH 2.85) (Table 1) and the carbonyl group at ring C. In the
JMOD spectrum 19 carbon signals were observed (Table 2).
The methoxy group was located at C-8a, as the aforemen-
tioned CH3O proton signal showed HMBC correlation with
the carbon signal resonating at δC 73.8. Following the NMR
studies the enantiomers 4a and 4b were separated on a Lux
amylose-1 chiral-phase HPLC column [tR = 5.5 min (4a) and
10.3 min (4b)].
The 1D NMR data of compound 5 were found to be similar
to those of 2a and 2b, except for the presence of two ethoxy
groups in the molecule [δH 2.96, dq/3.29, dq, 2.76 dq/3.08, dq
(CH2) and 0.80, t/1.11, t (CH3); δC 59.0/60.2 (CH2), 14.7/
15.8 (CH3)]. Relevant HMBC interactions suggested the side
chains to be attached to the phenanthrene skeleton at C-4a and
C-8a (Tables 1 and 2).
Compounds 6a and 6b were obtained as racemic
diastereomers. The difference between compounds 1a−d and
compounds 6a and 6b involved the replacement of the C-1
and C-8a methoxy groups with ethoxy substituents (Tables 1
and 2).
Compounds 7a and 7b differ from compounds 4a and 4b in
the presence of an ethoxy group [δH 2.92, m, 3.11, m (CH2),
0.86, t (CH3); δC 59.5 (CH2), 15.4 (CH3)] at C-8a instead of a
methoxy group (Tables 1 and 2). Compounds 7a and 7b,
similar to 1a−d and 4−6, also contain a carbonyl moiety at C-
6 (δC 186.6). Following the NMR analysis, the enantiomers 7a
and 7b were separated by HPLC on a Lux amylose-1 chiral-
phase column [tR = 4.7 min (7a) and 9.1 min (7b)] and
mirror-image ECD spectra were recorded (Figure 6).
For the configurational assignments of 7a and 7b, the above-
mentioned TDDFT-ECD protocol was applied to (R)-7 and
also on the truncated methoxy model compound (R)-4.
DFT reoptimization of the initial six MMFF conformers of
both (R)-4 and (R)-7 yielded six conformers above 1%
population indicating that the ethoxy group does not have
considerable freedom (Figure S64, Supporting Information).
The Boltzmann-weighted ECD spectra of both sets of
conformers reproduced well the experimental ECD spectrum
of the first-eluting enantiomer 7a (Figure 7 and Figure S37,
Supporting Information). Consequently, the absolute config-
urations of 7a and 4a, which were separated under the same
conditions, could be elucidated as (R) and that of the second-
eluting 7b and 4b as (S).
Interestingly, racemic compound 8 is the only one in which
ring C is unchanged compared to the starting material,
juncuenin B. An ethoxy group [δH 3.00, dq, 3.28, dq (CH2),
1.20, t (CH3); δC 62.2 (CH2), 15.8 (CH3)] is attached at C-1,
and the phenolic group at C-2 of juncuenin B was oxidized to a
carbonyl moiety (δC 202.9). Moreover, 8 is an unsaturated
compound containing a Δ9,10 double bond (δH 8.15, d and
7.61, d, H-9−H-10).
Compound 9 is a unique derivative because an ethoxy group
[δH 3.13, dq, 3.26, dq (CH2), 1.17, t (CH3); δC 61.6 (CH2),
15.6 (CH3)] is attached to the phenanthrene skeleton at C-7,
as suggested by spectroscopic data evidence. The HMBC
correlation of H3-12 (δH 1.49) with the oxygen-bearing C-7 at
δC 82.1, as well as the relevant cross peaks H-5/C-7, H-13/C-
7, H-5/C-8a, and H-13/C-8a indicated the presence of a Δ8,8a
double bond instead of a Δ7,8 olefinic bond, to support the
above conclusion.
In the case of compound 10, it was apparent from the 1D
NMR spectra that three n-butoxy groups are connected to the
phenanthrene skeleton. Both the phenolic substituents of
juncuenin B were oxidized to carbonyl groups, and a Δ9,10
double bond was also formed. The location of the methyl,
vinyl, and n-butoxy groups were determined by their diagnostic
HMBC correlations. Three-bond heteronuclear interactions of
C-1 (δC 81.9) with the oxymethylene protons at δH 2.92, m,
and of the deshielded C-5 (δC 94.6) with two additional
oxymethylenes at δH 3.14, m, and 3.54, m confirmed the
positions of the n-butoxy groups at C-1 and C-5, respectively.
The 1H NMR spectrum of the racemic compound 11
displayed signals attributable to an n-butoxy moiety [δH 2.83,
m, 3.07, m (CH2), 1.13−1.23, m (CH2) 0.86−1.03, m (CH2),
and 0.62, t (CH3); δC 63.5 (CH2), 31.9 (CH2), 19.1 (CH2),
and 13.7 (CH3)]. Since the oxidative transformation was
Figure 6. Experimental ECD spectra of 7a and 7b in MeCN.
Figure 7. Experimental ECD spectrum of 7a in MeCN (black line)
compared with the calculated CAM-B3LYP/TZVP PCM/MeCN
spectrum of (R)-7a (olive line). Level of DFT optimization: ωB97X/
TZVP PCM/MeCN. Bars represent the rotational strengths of
conformer A.
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performed in a reaction medium containing n-BuOH as
solvent, and the aromatic A-ring and HO-2 remained intact
during the reaction, it was anticipated that the n-butoxy chain
is situated at C-8a. This presumption was corroborated by a
strong HMBC cross peak between the oxymethylene protons
and C-8a.
The antiproliferative assays of the products were carried out
by a standard MTT method on human breast (MCF-7,
T47D), cervical (HeLa, SiHa, C33A), and ovarian (A2780)
cancer cells, and NIH/3T3 mouse embryonic fibroblast cell
lines. In the first step, the diastereomeric and racemic mixtures
1−11 and the starting compound, juncuenin B, were tested to
obtain information about their antiproliferative activity. Among
the tested samples, compounds 1a−d, 4a+4b, 6a, 7a+7b, and
11 exhibited significant tumor cell proliferation inhibitory
activities with IC50 values close to that of juncuenin B (Table
3, and Tables S2 and S3, Supporting Information). The IC50
value of juncuenin B on MCF-7 cell line (11.7 μM) was
determined for the first time. Similar to the structural points of
view, it is evident that compounds without a p-quinol ring (3,
8, 9, and 10) and compounds with two p-quinol moieties (2a,
2b, 5) did not exert antiproliferative activity. Compounds
substituted at C-4a with an alkoxy group were also inactive.
Compounds 1a−d (IC50s 11.6 μM on MCF-7, 15.0 μM on
T47D, 15.6 μM on HeLa, 20.0 μM on SiHa, 6.7 μM on C33A,
and 7.7 μM on A2780, respectively), 4a+4b (IC50s 6.5 μM on
MCF-7, 1.9 μM on HeLa, 7.0 μM on C33A, and 9.1 μM on
A2780, respectively), and 7a+7b (IC50s 6.2 μM on MCF-7,
16.9 μM on T47D, 5.4 μM on HeLa, 6.1 μM on C33A and 5.9
μM on A2780, respectively) with the highest activity were
selected for further studies.
In the second step, the enantiomerically pure compounds
(1a, 1b, 1c, 1d, 4a, 4b, and 7b) were evaluated for their
antiproliferative activity against the same cell lines (Table 4).
Among these compounds, the highest activities were recorded
for 1c, 4a, and 7a, reaching or exceeding that of the positive
control cisplatin against HeLa and/or T47D cell lines. (R)-7a
was found to be the most promising compound with
substantial antiproliferative effects against all tested cell lines
except for SiHa, but it was inactive against the nontumoral
NIH/3T3 cells.
Compounds 4a, 4b, 7a, 7b, and 11 contain a nonoxidized A
ring and a C-ring comprising a p-quinol alkyl ether moiety.
Moreover, 4a and 4b are substituted with a methoxy-, 7a, and
7b with an ethoxy-, and 11 with an n-butoxy group at C-8a,
respectively. In the case of these compounds, the effect of the
length of the ether chain at C-8a is undefined: on the T47D,
HeLa, C33A, and A2780 cell lines, compound 7a with an
ethoxy group, showed the highest inhibition, while its
enantiomer (7b) had no activity. On the HeLa cell line, the
antiproliferative activity was inversely proportional to the chain
length of the alkoxy groups (IC50 values 11 > 7a > 4a).
Compounds 4a and 7a showed an antiproliferative effect on
HeLa, C33A, MCF-7, and A2780 cells, which was comparable
to or stronger than that of juncuenin B, while their
stereoisomers 4b and 7b had no relevant influence on the
cell proliferation, indicating that (8aR) is the preferred
absolute configuration of these compounds. Regarding the
pure enantiomers 1a−d, the (1S,8aR)-configuration (1c) was
the most beneficial for the antiproliferative effect. The activities
of (1S,8aR)-1c, (R)-4a, and (R)-7a suggest the preference of
the (R) configuration for the antiproliferative activity. Since 1a
is less active than 1c, the (1S) configuration seems to be also
essential in the case of quinoidal compounds.
It is worth mentioning that several of the semisynthetic
compounds demonstrated an altered cell line specificity as
compared to their parent compound, juncuenin B. For
example, while juncuenin B exerted approximately 2.5-fold
stronger activity on MCF-7 than on T47D cells, a similar rate
of selectivity in the opposite direction was observed for the
enantiopure compound 7a. While both of these cell lines are
estrogen receptor α positive and therefore estrogen-dependent,
they show critical differences in their bioenergetic properties,21
as well as in apoptotic events including the activation of
different caspases and mitochondrial changes.22 This selectivity
inversion suggests that compounds obtained from juncuenin B
Table 3. IC50 Values (μM, Mean ± SEM) of the Diastereomeric and/or Racemic Mixtures
a
calculated IC50 values (μM ± SEM)
compound MCF-7 HeLa C33A A2780 NIH/3T3
juncuenin B − 2.9 ± 0.5b − 7.3 ± 1.3b >30
1a−1d − − 6.7 ± 0.5 7.7 ± 1.0 17.7 ± 0.7
4a+4b 6.5 ± 1.1 1.9 ± 0.4 7.0 ± 1.8 9.1 ± 0.5 14.9 ± 3.7
7a+7b 6.2 ± 0.2 5.4 ± 0.1 6.1 ± 0.4 5.9 ± 1.1 >30
cisplatin 5.8 − 1.8 1.3b 2.7
aCompounds 2a, 2b, 3, 5, 6b, 8, 9, and 10 were found to be inactive or moderately active (Table S1, Supporting Information). Determinations
were performed using an MTT assay by treating the cells with compounds (0.1−30 μM) for 72 h. Data are based on two independent experiments.
bIC50 value from literature.
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Table 4. IC50 Values of the Enantiopure Compounds 1a−1d, 4a, 4b, 7a, and 7ba
Calculated IC50 values (μM ± SEM)
compound MCF-7 T47D HeLa C33A A2780 NIH/3T3
(1R,8aS)-1b − − − − 9.0 ± 1.0 >30
(1S,8aR)-1c − − − 5.3 ± 0.9 7.7 ± 0.6 21.6 ± 0.4
(8aR)-4a 6.2 ± 1.6 − 0.9 ± 0.4 5.3 ± 0.6 8.7 ± 0.8 25.8 ± 4.6
(8aR)-7a − 8.8 ± 1.1 3.7 ± 0.9 4.9 ± 0.3 2.8 ± 0.3 >30
cisplatin 5.8 9.8b −b 1.8 1.3b 2.7
aDeterminations were performed using an MTT assay by treating the cells with compounds (0.1−30 μM) for 72 h. Data are based on two
independent experiments. bIC50 value from literature.
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were not only more potent than the starting material, but also
these compounds likely act on different biochemical targets.
Further studies are necessary for the clarification of these
targets, but chemical analogies from our previous work suggest
the involvement of ATR-dependent signaling at least to some
extent.12,13
In conclusion, oxidation of juncuenin B with hypervalent
iodine reagents under different conditions resulted in the
identification of phenanthrene derivatives substituted with
hydroxy, methyl, methoxy, vinyl, ethoxy and n-butoxy groups.
The majority of the components contain a substituted p-quinol
ring. All compounds are reported here for the first time. Several
compounds showed promising antiproliferative activities, and
based on their structural analogy, structure−activity relation-
ships were deduced. No significant activities were observed
either for compounds without a substituted p-quinol ring (3, 8,
9, and 11), or for those containing two such rings (2a, 2b, and
5). However, derivatives containing one substituted p-quinol
ring showed promising antiproliferative activities against
different human cancer cell lines, and this was observed for
compounds with an o-alkoxy-quinone moiety (1a−d, 6a) and
for those with an intact A ring (4a, 7a, and 11). Clarifying the
mechanism of action for these compounds requires further
studies.
In the current work, similar structural elements were
introduced in juncuenin B as present in denbinobin and
calanquinone. The aromatic ring oxidations of juncuenin B
afforded quinols which were found to be bioactive to the same
degree as the lead compounds denbinobin and calanquinone.
The starting compound juncuenin B can be readily isolated in
a good yield (0.043% w/w) from Juncus inf lexus root. There is
a strong rationale for further development of oxidized
derivatives of juncuenin B in the future.
■ EXPERIMENTAL SECTION
General Experimental Procedures. NMR spectra were
recorded in methanol-d4 and CDCl3 on a Bruker Avance DRX 500
spectrometer at 500 MHz (1H) and 125 MHz (13C). The signals of
the deuterated solvents were used as references. The chemical shift
values (δ) are given in ppm and coupling constants in Hz. 2D
experiments were performed with standard Bruker software. In the
1H−1H COSY, HSQC, and HMBC experiments, gradient-enhanced
versions were applied. The HRMS data were acquired on a Thermo
Scientific Q-Exactive Plus Orbitrap mass spectrometer equipped with
ESI ion source in positive ionization mode. The data were acquired
and processed with MassLynx software. ECD and UV spectra were
recorded on a J-810 spectropolarimeter.
In the reaction processes [bis(trifluoroacetoxy)iodo]benzene
(PIFA) and (diacetoxyiodo)benzene (PIDA) were used as oxidizing
agents (Sigma-Aldrich, Stockholm, Sweden). To reaction progress
and separation steps were monitored by TLC on Kieselgel 60F254
silica plates obtained from Merck (Merck, Darmstadt, Germany), and
examined under UV light at 254 and 366 nm. Solid phase extraction
(SPE) was carried out on silica gel (Kieselgel 60 GF254, 15 μm,
Merck). MPLC was performed with a Combi Flash Rf+ Lumen
instrument (Teledyne Isco). All solvents used for MPLC were of at
least analytical grade (VWR Ltd., Szeged, Hungary). Both the reaction
mixtures and processed fractions were investigated by HPLC on a
Jasco instrument equipped with an MD-2010 Plus PDA detector
(Jasco Analytical Instruments, Japan) in a detection range of 210−400
nm, with an Agilent Eclipse XDB C8 column (4.6 × 150 mm, 5 μm)
(Agilent Technologies, Inc., USA). MeCN−H2O solvent system was
used as eluent. The final purification steps were carried out by using
HPLC with an Agilent Eclipse XDB C8 (9.4 × 250 mm, 5 μm)
(Agilent Technologies, Inc., USA) equipment, and MeCN−H2O
mixture as the mobile phase. Enantiomers were separated by using a
Lux amylose-1 column (250 × 21.2 mm) (Phenomenex, USA), using
a cyclohexane−isopropanol solvent system as mobile phase. The
HPLC system for semipreparative separations comprised of a Waters
600 controller, Waters 600 pump, and Waters 2998 photodiode array
detector. The data were acquired and processed with the Empower
software.
The antiproliferative activity and tumor selectivity of the
compounds were measured by standard MTT assays. Tumor cell
lines MCF-7, T47D, HeLa, A2780, and noncancerous NIH/3T3 were
provided by European Collection of Authenticated Cell Cultures
(ECACC, Salisbury, UK); cell lines SiHa and C33A by LGC
Standards GmbH (Wesel, Germany). All chemicals and materials
used for the antiproliferative assays were purchased from Sigma
Aldrich Ltd. (Budapest, Hungary).
Juncuenin B. Juncuenin B was isolated previously from the
MeOH extract of Juncus inf lexus roots by chromatographic methods
(VLC on silica gel, and gel chromatography on Sephadex LH-20).
J. inf lexus is a good source of this compound as approximately 1.5 g
was isolated (0.043% w/w) in crystalline form from 3.5 kg dried plant
material.23
Synthesis and Purification Process. In reaction I, 50 mg
juncuenin B was dissolved in MeCN−MeOH (9:1) at a concentration
of 1 mg/mL, and stirred with 2 equiv of PIFA (161.2 mg) for 30 min
at 0 °C. After drying under nitrogen gas, SPE was applied to absorb
the remaining oxidizing agent and the possibly decomposed
compounds. Thereafter, the reaction mixture was fractionated by
MPLC with n-hexane−EtOAc gradient solvent system to obtain five
fractions (I/1−5). From fraction I/1 compounds 1a−d (1.00 mg, 2%
each) were isolated by RP-HPLC using MeCN−H2O (1:1) as eluent
(3 mL/min flow rate). Fraction I/2 was purified by RP-HPLC,
MeCN−H2O (3:2) (3 mL/min flow rate) was applied as eluent to
gain compounds 2a (0.88 mg) and 2b (0.75 mg).
For process reaction II, 100 mg juncuenin B was dissolved in
anhydrous MeOH at a concentration of 1 mg/mL, and stirred with 2
equiv of PIFA (322.32 mg) for 30 min at room temperature. After
evaporating the solvent under reduced pressure, SPE was applied to
absorb the remaining oxidizing agents and the possibly decomposed
compounds. The mixture was fractionated by MPLC with n-hexane−
EtOAc gradient solvent system to obtain four fractions. Fraction II/1,
after being chromatographed by RP-HPLC using MeCN−H2O (1:1)
(flow rate 3 mL/min) as mobile phase, compounds 1a−d (2.00 mg)
and 5 (3.8 mg) were obtained. Fractions II/2 and II/3 were separated
under the same conditions as II/1. From fraction II/2 1a−d (1.00
mg) and 3 (1.8 mg); from II/3 compounds 1a−d (3.00 mg) and 4a,b
(2.00 mg) were isolated.
In the case of reaction III, 100 mg juncuenin B was dissolved in
anhydrous EtOH at a concentration of 1 mg/mL, and stirred with 2
equiv of PIFA (322.32 mg) for 30 min at room temperature. After
evaporating the solvent under reduced pressure, SPE was applied to
remove the remaining oxidizing agents and decomposed compounds.
The mixture was fractionated by MPLC with a gradient solvent
system of n-hexane−EtOAc to obtain 10 fractions (III/1−10).
Fraction III/1 afforded compound 5 (1.6 mg) after purification by
HPLC with MeCN−H2O (1:1) as mobile phase (flow rate 3 mL/
min). Fraction III/2 was rechromatographed by RP-HPLC, using an
MeCN−H2O gradient system (flow rate 3 mL/min) as eluent to yield
compounds 6a (3.0 mg) and 6b (1.85 mg). Fraction III/4 was found
to be pure and gave compounds 7a,b (13.0 mg). Fraction III/6 was
subjected to HPLC using MeCN−H2O (1:1) (flow rate 3 mL/min)
as mobile phase and afforded compounds 7a,b (4.4 mg, 4.4%) and 8
(2.1 mg). Fraction III/7 was purified by RP-HPLC with MeCN−H2O
(1:1) as eluent to give compound 9 (1.80 mg).
In reaction IV, 50 mg juncuenin B was dissolved in n-BuOH at a
concentration of 1 mg/mL, and stirred with 2 equiv of PIFA (161,15
mg) for 30 min at room temperature. After evaporating the solvent
under reduced pressure, prepurification with SPE was performed and
the resulting mixture was fractionated by MPLC with an n-hexane−
EtOAc gradient system to afford six fractions (IV/1−6). From
fraction IV/1 compound 10 (1.80 mg) was isolated.
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For reaction V, 100 mg juncuenin B was dissolved in n-BuOH at a
concentration of 1 mg/mL, and stirred with 2 equiv of PIDA (242
mg) for 30 min at room temperature. The solvent was evaporated
under reduced pressure, and then SPE was used to absorb the
remaining oxidizing agents and other impurities. The mixture was
fractionated by MPLC with an n-hexane−EtOAc gradient solvent
system to afford four fractions (V/1−4). Fraction V/2 was subjected
to HPLC, eluting with MeCN−H2O (3:2) (flow rate 3 mL/min) as
mobile phase to give compound 11 (5.5 mg).
Separation of Enantiomers. Racemic mixtures, which had high
antiproliferative activity, were separated on a Lux amylose-1 chiral-
phase column in order to compare the antiproliferative activity of the
pure enantiomers. For the separation of compounds 1a−d, cyclo-
hexane−isopropanol (95:5) and for compounds 4a+b and 7a+b
cyclohexane−isopropanol (8:2) solvent systems (15 mL/min) were
used as eluent.
(1R,8aR)-1a. Pale yellow solid; [α]D: −17 (c 0.1, CHCl3);
HRESIMS m/z 327.1596 [M + H]+ (calcd for C20H23O4,
327.1592); UV (MeCN) λmax (log ε) 295sh (3.53), 220sh (3.95)
nm; ECD {CH3CN, λmax [nm] (Δε)}, c 5.97 × 10−4 M: 382 (−0.52),
341 (+2.05), 304sh (−0.67), 236 (−5.31), 207sh (−0.59); 1H and
13C NMR data, see Tables 1 and 2; HPLC: Lux amylose-1 chiral-
phase column, cyclohexane−isopropanol (95:5) solvent system, flow
rate 15 mL/min, tR = 13.6 min.
(1S,8aR)-1b. [α]D: −26 (c 0.1, CHCl3); UV (MeCN) λmax (log ε)
294sh (3.57), 221sh (4.01) nm; ECD {CH3CN, λmax [nm] (Δε)}, c
4.90 × 10−4 M: 393 (−0.74), 338sh (+0.80), 319 (+1.24), 246
(−4.01), 222sh (−2.92), 196 (+4.29); 1H and 13C NMR data, see
Tables 1 and 2. HPLC: Lux amylose-1 chiral-phase column,
cyclohexane−isopropanol (95:5) solvent system, flow rate 15 mL/
min, tR = 17.4 min.
(1S,8aS)-1c. [α]D: +26 (c 0.1, CHCl3); UV (MeCN) λmax (log ε)
294sh (3.57), 221sh (4.01) nm; ECD {CH3CN, λmax [nm] (Δε)}, c
5.31 × 10−4 M: 390 (+0.49), 336sh (−0.81), 317 (−1.14), 253sh
(+2.87), 237 (+3.81), 218sh (+2.27), 194 (−3.41); 1H and 13C NMR
data, see Tables 1 and 2. HPLC: Lux amylose-1 chiral-phase column,
cyclohexane−isopropanol (95:5) solvent system, flow rate 15 mL/
min, tR = 21.6 min.
(1R,8aS)-1d. [α]D: +23 (c, 0.1, CHCl3); UV (MeCN) λmax (log ε)
295sh (3.53), 220sh (3.95) nm; ECD {CH3CN, λmax [nm] (Δε)}, c
5.36 × 10−4 M: 384 (+0.39), 338 (−1.52), 303sh (+0.43), 236
(+3.79), 209sh (+0.49); 1H and 13C NMR data, see Tables 1 and 2.
HPLC: Lux amylose-1 chiral-phase column, cyclohexane−isopropanol
(95:5) solvent system, flow rate 15 mL/min, tR = 23.6 min.
Ent-2a. Pale yellow solid; HRESIMS m/z 327.1598 [M + H]+
(calcd for C20H23O4, 327.1591);
1H and 13C NMR data, see Tables 1
and 2.
Ent-2b. Pale yellow solid; HRESIMS see ent-2a; 1H and 13C NMR
data, see Tables 1 and 2.
Rac-3. White solid, HRESIMS m/z 325.1435 [M + H]+ (calcd for
C20H21O4, 325.1434);
1H and 13C NMR data, see Tables 1 and 2.
(8aR)-4a + (8aS)-4b. Pale yellow solid; HRESIMS m/z 297.1488
[M + H]+ (calcd for C19H21O3 297.1485);
1H and 13C NMR data, see
Tables 1 and 2; HPLC: Lux amylose-1 chiral column, cyclohexane−
isopropanol (8:2) solvent system, flow rate 50 mL/min, tR = 5.5 min
(4a) and 10.3 min (4b).
(4aR,S;8aR,S)-5. Pale yellow solid; HRESIMS m/z 355.1913 [M +
H]+ (calcd for C22H27O4 355.1904;
1H and 13C NMR data, see Tables
1 and 2.
Ent-6a. White solid; 1H and 13C NMR data, see Tables 1 and 2;
HRESIMS m/z 355.1903 [M + H]+ (calcd for C22H27O4 355.1904).
Ent-6b. White solid; 1H and 13C NMR data, see Tables 1 and 2;
HRESIMS see ent-6a.
(8aR)-7a. Pale yellow solid; [α]D: −124 (c, 0.1, CHCl3);
HRESIMS m/z 355.1915 (calcd for C20H23O3 355.1909); ECD
{CH3CN, λmax [nm] (Δε)}, c 5.07 × 10−4 M: 378 (−1.01), 333sh
(−0.23), 302sh (+0.19), 271 (+1.52), 250 (−1.13), 232 (+0.28), 218
(−0.84); 1H and 13C NMR data, see Tables 1 and 2; HPLC: Lux
amylose-1 chiral-phase column, cyclohexane−isopropanol (8:2)
solvent system, flow rate 15 mL/min, tR = 4.7 min.
(8aS)-7b. Pale yellow solid; [α]D: +148 (c, 0.1, CHCl3); HRESIMS
see (8aR)-7a; ECD {CH3CN, λmax [nm] (Δε)}, c 4.91 × 10−4 M: 379
(+2.48), 334sh (+0.55), 271 (−3.54), 250 (+2.89), 233 (−0.81), 217
(+1.94); 1H and 13C NMR data, see Tables 1 and 2. HPLC: Lux
amylose-1 chiral-phase column, cyclohexane−isopropanol (8:2)
solvent system, flow rate 15 mL/min, tR = 9.1 min.
Rac-8. White solid; HRESIMS m/z 309.1491 [M + H]+ (calcd for
C20H21O3 309.1485);
1H and 13C NMR data, see Tables 1 and 2.
Rac-9. White solid; HRESIMS m/z 311.1646 [M + H]+ (calcd for
C20H23O3 311.1642);
1H and 13C NMR data, see Tables 1 and 2.
Rac-10. Light brown solid; HRESIMS m/z 481.2948 [M + H]+
(calcd for C30H41O5 481.2949);
1H and 13C NMR data, see Tables 1
and 2.
Rac-11. Light brown solid; HRESIMS m/z 339.1959 [M + H]+
(calcd for C22H27O3 339.1955);
1H and 13C NMR data, see Tables 1
and 2.
Computational Methods. Mixed torsional/low-mode conforma-
tional searches were carried out by means of the Macromodel
10.8.011 software using the MMFF with an implicit solvent model for
CHCl3 applying a 21 kJ/mol energy window.
24 Geometry
reoptimizations of the resultant conformers (ωB97X/TZVP with
PCM solvent model for MeCN) and TDDFT ECD calculations were
performed with Gaussian 09.25 For ECD using various functionals
(B3LYP, BH&HLYP, CAM-B3LYP, PBE0) and the TZVP basis set
with the same solvent model as in the preceding DFT optimization
step. ECD spectra were generated as the sum of Gaussians with 3000
cm−1 half-height widths, using dipole-velocity computed rotational
strengths.26 Boltzmann distributions were estimated from the ωB97X
energies. The MOLEKEL program was used for visualization of the
results.27
Antiproliferative (MTT) Assay. Growth-inhibition properties of
racemates and pure enantiomer compounds were determined by
standard MTT assays on six human malignant gynecological cell lines
(MCF-7, T47D, HeLa, SiHa, C33A, A2780). To investigate tumor
selectivity, the MTT assay was repeated on mouse embryonic
fibroblast cells (NIH/3T3) under the same conditions. All cell lines
were maintained in minimal essential medium (MEM) supplemented
with 10% fetal bovine serum, 1% nonessential amino acids, and 1%
penicillin−streptomycin−amphotericin B mixture, and were stored in
humidified air containing 5% CO2 at 37 °C. All cell types were seeded
into 96−well plates at a density of 5000 with the exception of C33a,
which was seeded at a density of 10 000 and treated by increasing
concentrations (0.1−30 μM) of the compounds for 72 h under cell
culturing conditions. After the incubation, 5 mg/mL MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] solution was
added to samples for 4 h and precipitated blue formazan crystals were
dissolved in DMSO. Absorbance values of the samples were measured
at 545 nm using a microplate reader (Stat Fax-2100, Awareness
Technologies Inc., Palm City, FL, USA) and untreated cells were used
as control. Normalized sigmoidal dose−response curves were fitted to
the determined data and the IC50 values were calculated by GraphPad
Prism 5.01 (GraphPad Software, San Diego, CA, USA). Cisplatin
(Ebewe Pharma GmbH, Unterach, Austria) was used as a reference
agent in the same concentration range.
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Barbara Tóth − Department of Pharmacognosy,
Interdisciplinary Excellence Centre, University of Szeged,
6720 Szeged, Hungary
Judit Hohmann − Department of Pharmacognosy,
Interdisciplinary Excellence Centre, University of Szeged,
6720 Szeged, Hungary; orcid.org/0000-0002-2887-6392
Complete contact information is available at:
https://pubs.acs.org/10.1021/acs.jnatprod.0c00499
Author Contributions
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Kurtań, T.; Urbań, E.; Hohmann, J.; Chang, F. R.; Vasas, A. J. Nat.
Prod. 2016, 79, 2814−2823.
(24) MacroModel; Schrödinger, LLC, 2015. http://www.
schrodinger.com/MacroModel.
(25) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.;
Robb, M. A.; Cheeseman, J. R.; Scalmani, V.; Barone, G.; Mennucci,
B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H.
P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.;
Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.;
Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.;
Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.;
Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Kobayashi,
R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar,
S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox,
J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.;
Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.;
Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.;
Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A.
Journal of Natural Products pubs.acs.org/jnp Article
https://dx.doi.org/10.1021/acs.jnatprod.0c00499
J. Nat. Prod. 2020, 83, 3250−3261
3260
D.; Farkas, O.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J.
Gaussian 09, Revision E.01; Gaussian, Inc.: Wallingford, CT, 2013.
(26) Stephens, P. J.; Harada, N. Chirality 2009, 22, 229−233.
(27) Varetto, U. MOLEKEL 5.4; Swiss National Supercomputing
Centre: Manno, Switzerland, 2009.
Journal of Natural Products pubs.acs.org/jnp Article
https://dx.doi.org/10.1021/acs.jnatprod.0c00499
J. Nat. Prod. 2020, 83, 3250−3261
3261
